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Cocaine binds to the dopamine (DA) transporter (DAT) to regulate cocaine reward and seeking behavior. Zinc (Zn2+) also binds to
the DAT, but the in vivo relevance of this interaction is unknown. We found that Zn2+ concentrations in postmortem brain
(caudate) tissue from humans who died of cocaine overdose were significantly lower than in control subjects. Moreover, the level of
striatal Zn2+ content in these subjects negatively correlated with plasma levels of benzoylecgonine, a cocaine metabolite indicative
of recent use. In mice, repeated cocaine exposure increased synaptic Zn2+ concentrations in the caudate putamen (CPu) and
nucleus accumbens (NAc). Cocaine-induced increases in Zn2+ were dependent on the Zn2+ transporter 3 (ZnT3), a neuronal Zn2+
transporter localized to synaptic vesicle membranes, as ZnT3 knockout (KO) mice were insensitive to cocaine-induced increases in
striatal Zn2+. ZnT3 KO mice showed significantly lower electrically evoked DA release and greater DA clearance when exposed to
cocaine compared to controls. ZnT3 KO mice also displayed significant reductions in cocaine locomotor sensitization, conditioned
place preference (CPP), self-administration, and reinstatement compared to control mice and were insensitive to cocaine-induced
increases in striatal DAT binding. Finally, dietary Zn2+ deficiency in mice resulted in decreased striatal Zn2+ content, cocaine
locomotor sensitization, CPP, and striatal DAT binding. These results indicate that cocaine increases synaptic Zn2+ release and
turnover/metabolism in the striatum, and that synaptically released Zn2+ potentiates the effects of cocaine on striatal DA
neurotransmission and behavior and is required for cocaine-primed reinstatement. In sum, these findings reveal new insights into
cocaine’s pharmacological mechanism of action and suggest that Zn2+ may serve as an environmentally derived regulator of DA
neurotransmission, cocaine pharmacodynamics, and vulnerability to cocaine use disorders.
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INTRODUCTION
Zinc (Zn2+) is an essential trace element necessary for normal
brain function [1–6]. Within the brain it exists in two forms; a
“fixed”, protein-bound form, which serves as a catalytic co-factor
or as a structural component to Zn2+ binding proteins, and
comprises ~90% of total brain concentration, or a “free”, or labile/
chelatable form, comprising ~10% of total brain concentration.
Labile Zn2+ is also referred to as “synaptic” Zn2+ as it is localized
to synaptic vesicles in a subset of glutamatergic neurons, also
referred to as “zincergic” neurons [7]. Synaptic Zn2+ is found in
several regions such as cortex (Ctx, layers 2/3, 5, and 6),
hippocampus, striatum, amygdala and is generally not present
in thalamus [7, 8].
Synaptic Zn2+ levels are dependent on the Zn2+ transporter 3
(ZnT3) [9, 10], a neuronal-specific Zn2+ transporter localized to the
membrane of synaptic vesicles. ZnT3 knockout (KO) mice lack the
ability to package Zn2+ into these vesicles and consequently lack
synaptic Zn2+ release [9, 10]. ZnT3 KO mice are viable, fertile, and
do not show major behavioral abnormalities across spatial
learning, memory, or sensorimotor tasks, though they do exhibit
small deficits in skilled reaching tasks [11, 12], fear learning [13],
and sensory deficits [14, 15].
In terms of function, synaptic Zn2+ is released upon neuronal
activation, serves as a key regulator of neurotransmitter signaling,
and as such has also been referred to as a neurotransmitter [1–6].
Tonic extracellular Zn2+ concentrations are estimated to be at
<25 nM [16]. However, upon physiological zincergic neuron
activation and subsequent release, phasic Zn2+ concentrations
can increase up to 10 µM [17]. In this way, Zn2+ is thought to exert
various effects on neurotransmission by binding to synaptic
proteins that contain either low- or high-affinity Zn2+-binding
sites [6]. One such protein is the dopamine transporter (DAT),
which contains four high-affinity Zn2+-binding sites on its
extracellular domain [18–22].
Studies have shown that cocaine binds to the DAT to inhibit
synaptic DA reuptake, which leads to an increase of extracellular
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DA [23]. This mechanism underlies the direct subjective responses
that accompany cocaine use [24] and is critical to cocaine self-
administration (SA) in laboratory models, and cocaine reward and
abuse liability in humans [25]. In vitro assays have shown that
when Zn2+ binds to the DAT it promotes a conformation that
inhibits DA uptake and, when cocaine is present, Zn2+ can
increase cocaine’s affinity and can modulate its potency to inhibit
DA uptake [18–22]. Interestingly, synaptic Zn2+ is present in the
striatum [26, 27] where the DAT is found in the highest
concentration [28], and synaptic Zn2+ depletion in this region
improves motor deficits and memory impairments caused by loss
of striatal DAergic fibers [29]. These prior studies suggest that
synaptic Zn2+ may modulate in vivo DAT function and cocaine-
DAT pharmacodynamic interactions in the striatum. However, the
extent to which such interactions occur is unclear.
In addition to ZnT3, synaptic Zn2+ levels also depend on the
environmental availability of Zn2+ which is obtained exclusively
via the diet. Consequently, dietary factors which limit Zn2+ intake
influence both synaptic Zn2+ levels and ZnT3 expression [30, 31].
In fact, as the body lacks a specialized system for its storage, Zn2+
needs to be consumed continuously to avoid a state of deficiency
which itself can have profound changes in both the periphery as
well as in brain function [32]. Human drug users generally do not
follow a lifestyle that prioritizes nutritional needs and are known
to exhibit nutritional deficiencies including dysregulated blood
and hair Zn2+ content [33–38]. However, whether such deficits are
involved in the neurobiological changes associated with cocaine
use or use of other drugs is unknown.
METHODS
Subjects
De-identified postmortem human brain specimens were collected
during the routine autopsy process as described in detail previously
[39, 40]. Briefly, the cause and manner of death were determined by
forensic pathologists following medico-legal investigations that eval-
uated the circumstances of death including medical records, police
reports, autopsy results, and toxicological data. Inclusion in the cocaine
cohort (n= 20; 10 Caucasian, 10 African-American) was based on
cocaine abuse as the cause of death, a documented history of drug
abuse, and a toxicology positive for high levels of the cocaine
metabolite benzoylecgonine and, in most cases, the short-lived cocaine
adulterant levamisole, both indicative of recent cocaine use prior to
death. Control subjects (n= 20; 10 Caucasian, 10 African-American) died
as a result of cardiovascular disease or gunshot wound, had no
documented history of drug abuse, and tested negative for cocaine and
other drugs of abuse. Exclusion criteria for the study included a known
history of neurological or psychiatric illness, death by suicide, estimated
postmortem interval exceeding 20 h, evidence of neuropathology (e.g.,
encephalitis, stroke), or chronic illness (e.g., cirrhosis, cancer, HIV,
prolonged hospitalization). The final groups did not differ with regard to
age for race, nor with regard to brain pH, a well-established measure of
sample quality and perimortem agonal state [41]. Tissue from one
cocaine user was not included due to very high cocaine metabolite
levels.
Given that the human tissue samples available consisted only of males,
and therefore all human data were limited to this sex, we focused on male
mice for all other mechanistic experiments. Male C57Bl/6J mice were
acquired from Jackson Labs at 8 weeks of age. Breeding pairs of Slc30a3
(ZnT3) KO mice were obtained from Dr. Thanos Tzounopoulos at the
University of Pittsburgh and bred at the National Institute on Drug Abuse
(NIDA) (Baltimore, MD) on a C57Bl/6J background. Mice were genotyped
by Transnetyx (Cordova, TN). All mice were male and matched for age and
weight. Mice were single-housed during experimental testing in a
temperature and humidity-controlled environment on a regular light cycle
(on at 7 am and off at 7 pm). Food and water were available ad libitum and
mice were acclimated prior to any behavioral procedures by handling. All
experimental procedures were carried out in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals and
were approved by the Animal Care and Use Committee of NIDA.
Total reflection X-ray spectroscopy (TXRF)
Tissue samples were collected and weighed in 1.5 ml Eppendorf tubes. The
weight of the tissue was directly used to calculate element concentrations
in µg/kg units. Each tissue sample was dissolved in 100 µL of nitric acid
(Sigma: NX0408) with 2 µL of a gallium standard (conc. 1000 ppm). Each
sample was assessed in duplicate for TXRF elemental analysis using an S2
Picofox (Bruker, Billerica, MA). This instrument exposes the sample to an
X-ray beam and measures fluorescence radiation specific to the element(s)
of interest. Human samples were prepared from postmortem tissue
collected from the anterior caudate. Wild-type (WT) or ZnT3 KO mice
received either saline, a single cocaine injection (20mg/kg, i.p), or 8
repeated daily cocaine (20 mg/kg, i.p) injections and were euthanized 24 h
after the last injection. Mice fed the 30 ppm and 5 ppm Zn2+ diets were
exposed to each respective diet for 35 days and then euthanized. Mouse
samples were prepared by slicing flash-frozen tissue on a cryostat (100 µm
sections from Bregma 1.00 to 0.00mm) or dissecting the Ctx and striatum
from each section.
Synchrotron X-ray fluorescence microspectroscopy (µXRFS)
Brain concentrations and distributions of Zn2+ from C57BL/6J mice
injected with saline or cocaine (10mg/kg, i.p.) every other day for 8 days
and euthanized 24 h after the last injection were measured at the X26a
beamline at the National Synchrotron Light Source (NSLS) at Brookhaven
National Laboratory (Upton, NY). The synchrotron X-ray beam was tuned to
12 keV using a Si(111) channel-cut monochromotor. The monochromatic
beam was then collimated to 350 μm× 350 μm and then focused to
approximately 6 μm× 10 μm using Rh-coated silicon mirrors in a
Kirkpatrick–Baez (KB) geometry. The sample was placed at a 45° angle to
the incident X-ray beam and X-ray fluorescence was detected with an
energy dispersive, 9-element germanium array detector (Canberra,
Meriden, CT) oriented at 90° to the incident beam. The sample was
approximately 6 cm from the detector. A light microscope objective
(Mitutoyo, M Plan Apo 5X) was coupled to a digital CCD camera for sample
viewing. Energy dispersive spectra were collected by raster-scanning the
sample through the X-ray beam using a dwell time of 0.3 s/pixel and a step
size of 10 μm. Zn Kα, fluorescence counts were then extracted from
background-corrected energy dispersive spectra. All data were normalized
to variations in incident photon flux by normalizing to changes in I0
measured by ion chamber upstream of the KB optics. XRFS calibration
standards on Nuclepore® polycarbonate aerosol membranes expressing
known (±5%) concentrations of Zn (48.4 µg/cm2) were also imaged in
parallel to the samples (Micromatter, Vancouver, BC) and used to express
results as µg/cm2. Image analysis was carried out using ImageJ (National
Institutes of Health, Bethesda, MD). Regions of interest (ROI) were drawn
onto the Ctx, caudate putamen (CPu), nucleus accumbens (NAc), and
measurements for each ROI were obtained.
Zinc–selenium autometallography (ZnSeAMG)
WT and ZnT3 KO mice were anesthetized with a ketamine-xylazine cocktail
(ket = 60mg/kg + xyl = 12mg/kg) and injected (i.p.) with 15mg/kg sodium
selenite (Sigma Aldrich: 214485) and placed on a heating pad while
anesthetized for 60min. Mice were then perfused with 0.1M phosphate
buffer for 5min. Brain tissue was dissected, and flash frozen in dry ice cooled
isopentane and stored at −80 °C until sectioning. Coronal brain sections
(20 µm) were thaw mounted at the level of the striatum and hippocampus on
positively charged glass slides. Slides were stored at −20 °C until staining.
Slides were loaded in non-metallic staining racks and allowed to reach room
temperature. Slides were fixed in 95% ethanol for 15min followed by
hydration in 70% (2min) and 50% (2 min) ethanol ending in 3 × 2min distilled
water rinses. Slides were dipped in 0.5% gelatin and air dried prior to physical
development. Developer was made by mixing Gum Arabic (50% solution,
100ml), citrate buffer (2.0M, 20ml), hydroquinone (1.7 g in 30ml DDH2O),
silver lactate (0.22 g in 30ml H20), and DDH2O (200ml). Developer was poured
onto slides, incubated for 60min in the dark then quickly checked at 10min
intervals until sections are dark brown. Slides were washed in slowly flowing
tap water (37 °C) for 10min to remove gelatin then rinsed 3 × 2min in distilled
water. Slides were then incubated in 5% sodium thiosulphate (12min) and
rinsed 2 × 2 min in distilled water and post-fixed in 70% ethanol (30 min).
Optional counter stain using cresyl violet or toluidine blue (5 min) followed by
rinse 4 × 30 s rinse in distilled water. Finally, slides were dehydrated in 95%
ethanol (5 min), 100% ethanol 2 × 5 min, xylene 2 × 5 min, and coverslipped
with permount. Stained sections were imaged using brightfield microscopy.
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65Zn uptake experiments using positron emission
tomography (PET)
WT and ZnT3 KO mice were anesthetized with isoflurane and placed in a
prone position on the scanner bed of a nanoScan PET/CT (Mediso, USA)
injected intravenously (~150 µL) with 65ZnCl2 (~2.2 MBq) and PET data
were acquired for 2 h followed by a CT scan. After scanning, animals were
returned to their home cage. Scans were repeated on days 1, 3, 7, and 14.
For cocaine experiments, C57Bl/6J mice were injected with 65ZnCl2 as
above and then injected immediately with saline or cocaine (20mg/kg, i.p).
Saline and cocaine injections continued daily for 7 days. Mice were
scanned on Day 1 and Day 7 after 65ZnCl2 injection as above. In all cases,
the PET data were reconstructed and corrected for dead-time and
radioactive decay. Qualitative and quantitative assessments of PET images
were performed using the PMOD software environment (PMOD Technol-
ogies, Zurich Switzerland). Time-activity curves were generated using
manually drawn volumes of interest using the CT image as a reference.
Standardized uptake values (SUV) were calculated using the formula SUV(i)
= C(i)/(ID × BW) where C(i) is the activity value at a given time point (in
kBq/cc), ID is the injected dose (in MBq) and BW is the animal’s body
weight (in kg). For voxel-wise analyses we used Statistical Parametric
Mapping (SPM12, London, UK) as previously described [42]. First, all the
images were co-registered and masked to the reference mouse atlas in
PMOD. Regional changes in uptake were assessed relative to global
(whole-brain) uptake. For the cocaine experiments, a repeated measures
(RM) analysis of variance (ANOVA) model was used that defined saline vs.
cocaine-treated mice scanned at 1 and 7 days post 65ZnCl2 injection.
Images were subtracted after intensity normalization to 100 by the
proportional scaling method. After estimation of the statistical model, a
contrast (Cocaine > Vehicle) was applied to reveal the effects of interest.
These effects were overlaid on the reference MRI. An uncorrected P value
of 0.05 with a cluster threshold value of 50 were used as thresholds to
determine statistical significance.
Ex vivo 65Zn autoradiography
One day after the last PET scan, WT and ZnT3 KO mice were euthanized
and brain tissue was dissected, flash frozen in isopentane, and stored at
−80 °C until sectioning. Tissue was sectioned and thaw mounted on
positively charged glass slides. Slides were placed on BAS-IP SR 2040 E
Super Resolution phosphor screens (GE Healthcare) for 14 days and
imaged using a phosphor imager (Typhoon FLA 7000; GE Healthcare).
Radioligand binding assays
Brains from euthanized C57Bl/6J mice were removed and striata dissected
and quickly frozen until use. The tissue was weighed and suspended in ten
times (w/v) of ice-cold Tris-HCl buffer (50 mM, pH 7.4). The suspension was
homogenized with a Polytron homogenizer (Kinematica, Basel, Switzer-
land) under ice. Homogenates were centrifuged at 48,000 × g (50min, 4 °C)
and washed twice in the same conditions to isolate the membrane
fraction. Protein was quantified by the bicinchoninic acid method (Pierce).
For competition experiments, membrane suspensions (50 µg of protein/
ml) were incubated in 50mM Tris-HCl (pH 7.4) 0.5 nM of [3H]WIN-35428
(Perkin-Elmer) and increasing concentrations of the indicated competing
drugs (WIN-35428 or cocaine) in the presence or the absence of 100 nM,
10 μM or 1mM of ZnCl2 during 2 h at RT. Nonspecific binding was
determined in the presence of 100 µM cocaine. In all cases, free and
membrane-bound radioligand were separated by rapid filtration through
Whatman (Clifton, NJ) GF/B filters, pre-soaked in 0.05% polyethyleneimine
by using a Brandel R48 filtering manifold (Brandel Inc., Gaithersburg, MD).
The filters were washed twice with 5ml of cold buffer and transferred to
scintillation vials. Beckman Ready Safe scintillation cocktail (3.0 ml) was
added, and the vials were counted the next day with a Beckman 6000
liquid scintillation counter (Beckman Coulter Instruments, Fullerton, CA) at
50% efficiency.
In vitro autoradiography using [3H]WIN-35,428
Brain tissue from WT and ZnT3 KO mice was dissected, flash frozen in
isopentane, and stored at −80 °C until sectioning. Tissue was sliced on a
cryostat at 16 µm and thaw mounted on positively charged glass slides
and stored at -20 °C until autoradiography. Incubation Buffer consisted of
50 mM Tris-HCl (7.4 pH) and 100 mM NaCl in deionized water. [3H]WIN-
35,428 Total binding buffer (S.A. 82.9 Ci/mmol, Conc. 1 mCi/ml) was made
in incubation buffer at a concentration of 10 nM. ZnCl2 binding buffer was
made using the Total binding buffer stock and adding ZnCl2 for a
concentration of 10 µM. Slides were pre-incubated in ice-cold incubation
buffer for 20min then transferred to respective radioactive incubation
buffers (i.e. total or total+ZnCl2) for 120min on ice. Slides were then
washed 2 × 1min in ice-cold 50 mM Tris-HCl (pH= 7.4) then dipped (30 s)
in ice-cold deionized water. Slides were dried under stream of cool air and
placed on BAS-IP TR 2025 E Tritium Screen (GE Healthcare) for 5 days and
imaged using a phosphor imager (Typhoon FLA 7000; GE Healthcare).
Sections were analyzed using Multigauge software (Fujifilm, Japan).
In vivo fast scan cyclic voltammetry (FSCV)
FSCV procedures follow those of recently published work from our
laboratory in anesthetized mice using electrical stimulation [43]. Briefly,
glass sealed 100 µm carbon-fiber microelectrodes were pre-calibrated with
known concentrations of dopamine and changes in pH to allow for a
principal component analysis (PCA) of the raw data using HDCV (UNC,
Chapel Hill, NC). Dopamine was identified by cyclic voltammogram using a
voltage scan from −0.4 to 1.3 V at 400 V/s. During the experiment an
external stimulus was applied using the tungsten electrode every 5 min
comprised of 24 pulses 4ms in width at 60 Hz and 180 µA while the
working electrode was implanted in the striatum (AP: +1.5 mm; ML:
±1.0mm; DV: −3.2 to −3.7 mm from bregma). After PCA data were
analyzed to determine the DAMax and DA clearance rate using a custom
macro written in Igor Carbon Pro which identified peaks greater than 3×
root mean square noise and fit to Eq. 1 where DAMax represents the peak
DA concentration measured, k is the rate constant, and t is time [43].
DA tð Þ ¼ DAMaxek tt0ð Þ (1)
Cocaine locomotor sensitization
Each session during the development phase was 30min, and mice were
only exposed to one session per day with locomotor activity quantified as
distance traveled (cm). All injections were administered (i.p.). Mice were
first habituated to the locomotor activity chambers (Opto-varimex ATM3,
Columbus Instruments). On the next two sessions, mice were injected with
saline and placed in the chambers. On the following five sessions, separate
groups were injected with either saline or cocaine (10 mg/kg) in a
counterbalanced design. Mice were then allowed 7 days of withdrawal in
the colony room and then returned to the behavior room for testing
expression of sensitization. Briefly, all mice were allowed access to the
activity chambers for 60min followed by increasing doses of cocaine
(saline, 5, 10, 20 mg/kg) every 60min. Data collection was paused but
chambers were not cleaned in-between cocaine dosing, each mouse was
picked up, injected, and placed back in chamber to continue data
collection.
Cocaine conditioned place preference (CPP)
The task consisted of ten sessions, one per day, in chambers with two
visually distinct sides, one with clear walls and white floor and one with
checkered walls and black floor. The sides were divided by a door with and
without access to the other side. Locomotor activity was measured by way
of time spent in each chamber as well as total distance traveled (Opto-
varimex ATM3, Columbus Instruments). In the first session, the mice could
explore both sides of a conditioning box for 15min to determine inherent
side preference, designated as the Pre-Test. Using this data, the cocaine-
paired side was pseudo-randomized so that mice with a preference for one
side (>60%) were cocaine-paired on the other, non-preferred side. Mice
with no side preference were cocaine-paired in a counterbalanced fashion.
Separate groups of mice were conditioned with either a 5, 10 or 20mg/kg
dose of cocaine. In an alternating fashion for 8 days, mice were injected
(i.p.) with either saline or cocaine and placed in the predetermined drug/
no drug side of the chamber for 30min. The mice had no physical access
to the other side but were still able to see through the clear divider wall.
Each mouse had a total of 4 saline-paired days and 4 cocaine-paired days.
The last session was the same as the first and designated the Test session.
Time spent in the cocaine-paired chamber during the Pre-Test session
(prior to conditioning) was subtracted from time spent in the cocaine-
paired chamber during the Test session and expressed as the
Preference score.
Mouse intravenous cocaine self-administration
Mice were implanted with jugular vein catheters under ketamine/xylazine
anesthesia and using aseptic surgical techniques. A 6.0 cm length
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MicroRenathane (ID 0.012″, OD 0.025″; Braintree Scientific Inc., Braintree,
MA, USA) catheter was inserted 1.2 cm into the right jugular vein and
anchored to a 24-gauge steel cannula (Plastics One, Roanoke, VA, USA) that
was bent at a 100° angle and mounted to the skull with cyanoacrylate glue
and dental acrylic. A 2.5 cm extension of flexible tubing was connected to
the distal end of the cannula. The mice were allowed 5–7 days for recovery,
during which time 0.05 ml of a 0.9% saline solution containing 20 IU/ml
heparin and 0.33 mg/ml gentamycin was infused daily through the
catheter to prevent catheter clotting and infection. Thereafter, 0.05 ml of
0.9% saline solution containing 20 IU/ml heparin was infused immediately
prior to and immediately following each daily SA session. When needed,
i.v. brevital (a barbiturate) was used to test catheter patency between the
SA sessions. During cocaine SA sessions, the flexible tubing extension was
connected to a perfusion pump (Med Associates, Fairfax, VT) via a PE50
tubing connector. After daily SA sessions, the free end of the cannula guide
was always kept sealed.
Operant test chambers (Med Associates, Fairfax, VT) contained two
levers (active and inactive) located 2.5 cm above the floor as well as a cue
light above each lever. A house light mounted on the opposite side of the
chamber signaled the start of each 3 h session and remained illuminated
until the session ended. For SA sessions, a liquid swivel mounted on a
balance arm above the chamber allowed for i.v. drug delivery in freely
moving mice. Depression of the active lever resulted in the activation of an
infusion pump; depression of the inactive lever was recorded but had no
scheduled consequences. Each infusion was paired with two discrete cues:
illumination of the cue light above the active lever, and a cue tone that
lasted for the duration of the infusion. Experimental events were controlled
by a PC programmed in Medstate Notation and connected to a Med
Associates interface.
After recovery from surgery, mice were placed into operant chambers
and allowed to lever press for i.v. cocaine SA under a fixed-ratio 1
reinforcement schedule (i.e., each lever press leads to one cocaine
infusion) for 3 h daily. Each cocaine infusion lasted 4.2 s, during which
additional active lever responses were recorded but had no consequences
(i.e., non-reinforced active lever response). Mice were trained initially for a
high unit dose of cocaine (1 mg/kg/infusion) to potentiate acquisition of
SA until stable SA was achieved, which was defined as earning at least 20
infusions per 3 h session and an active/inactive lever press ratio exceeding
2:1. Then the mice were switched to a multiple-dose schedule to observe
the dose-dependent cocaine SA according to a descending cocaine dose
sequence from the initial dose of 1 mg/kg/infusion (sessions 1–13) to
0.5 mg/kg/infusion (sessions 14–20), 0.25 mg/kg/infusion (sessions 21–23),
0.125mg/kg/infusion (sessions 24–27), and 0.0625mg/kg/infusion (ses-
sions 28–29). Mice that did not reach stability criteria, lost catheter patency
or showed excessive high-level inactive lever responding (>100 presses
per session) were excluded from further experimentation. To prevent
cocaine overdose, maximally allowed cocaine infusions were 50 (0.1 and
0.5 mg/kg/infusion), 100 (0.25mg/kg/infusion), 200 (0.125 mg/kg/infusion),
or 400 (0.0625mg/kg/infusion), respectively during each 3-h session. The
number of cocaine infusions earned, and active and inactive lever
responses were recorded for each session. The last 2–3 days of cocaine
SA data at each dose were averaged and used to compare dose-response
performance between WT and KO mice.
After the completion of the above cocaine dose–response experiment,
the animals were switched to cocaine SA under PR reinforcement
schedule. During PR conditions, the work requirement (lever presses)
needed to receive a cocaine infusion was raised progressively within each
test session according to the following PR series: 1, 2, 4, 6, 9, 12, 15, 20, 25,
32, 40, 50, 62, 77, 95, 118, 145, 178, 219, 268, 328, 402, 492, and 603 until
the breakpoint was reached. The breakpoint was defined as the maximal
workload (i.e., number of lever presses) completed for the last cocaine
infusion prior to a 1-h period during which no infusions were obtained by
the animal. Animals were tested for cocaine SA under PR reinforcement at
three doses (starting at 0.25, then 1 and then 0.5 mg/kg/infusion) from
days 30 to 38.
After the completion of the PR experiments, the same groups of animals
continued for cocaine extinction and reinstatement tests. During extinc-
tion, syringe pumps were turned off and the cocaine-associated cue light
and tone were unavailable. Thus, lever pressing was recorded but had no
scheduled consequences. Extinction training continued for about 20 days
until the extinction criteria were met (i.e., lever responding <20% of the SA
baseline) for at least 3 sessions. Mice then received a 10mg/kg i.p cocaine
injection to evoke reinstatement of drug-seeking behavior. During
reinstatement testing, active lever presses lead to re-exposure to the cue
light and tone previously paired with cocaine infusions, but not to actual
cocaine infusions. Active and inactive lever responses were recorded for
each extinction and reinstatement session. Lever pressing behavior during
the cocaine-primed session was compared to the average lever pressies
during the last 3 days of extinction.
Custom diets
Diets were formulated by Research Diets, Inc via use of AIN-93M mature
rodent diet. The diets were compositionally identical, but one diet had an
adequate amount of Zn2+ (30 ppm) and the other diet had a deficient
amount of Zn2+ (5 ppm). Zn2+ concentration in each diet was confirmed
in-house via random sampling of chow pellets and TXRF (S2 Picofox,
Bruker, Billerica, MA).
Body weight and food intake measurements
C56BL/6J mice arrived at the NIDA mouse colony and were allowed one
week of environmental acclimation with regular chow and water available
ad lib. After the acclimation period, mice were given a diet containing
either 30 ppm Zn2+ or 5 ppm Zn2+ for a minimum of 35 days prior to any
behavioral manipulations. Mice stayed on the diet until the completion of
the experiment. Mice were individually housed and weighed three times
per week along with food weight to track the amount of food consumed.
Immunohistochemistry
Coronal sections were sliced on a cryostat (30 µm), collected in six-well
plates with PBS, and stored at 4 °C until use. Sections were transferred to
12-well plates and permeabilized in washing buffer (PBS + Triton X-100
0.1%) for 10 min at room temperature on a shaker. Tissue was blocked in
blocking buffer (BSA 3% + PBS + Triton X-100 0.1%) for 60 min at RT on
shaker. Tissue was incubated overnight in primary ZnT3 antibody (1:500)
(anti-rabbit, #197 003, Synaptic Systems, Goettingen, Germany) at 4 °C.
Tissue was washed with washing buffer 3 x 10 min at RT then incubated in
secondary antibody (Alexa 488-Rabbit #A1134, Thermo Fisher (1:400),
Topro (1:1200), and DAPI (1:600) for 2 h at RT in the dark. Tissue was
washed with washing buffer 3 × 10 min, transferred to dish with PBS,
mounted on positively charged glass slides, and coverslipped with
aqueous mounting medium (90% glycerol + 30 mM Tris-HCl, pH 8.0)
and imaged using confocal microscopy.
Statistics
Sample sizes were estimated based on prior experience with the specific
assays/experiments and expected effect sizes. Mice (with the exception of
ZnT3 KO) were randomly selected from littermates into experimental
groups. Experiments were performed unblinded. Depending on experi-
ment, we used linear regression, unpaired t-tests, one sample non-
parametric (Wilcoxon) tests, one or two-way ANOVA or a mixed effects
model (to account for missing data) taking RM into account when
appropriate. Significant main or interaction effects were followed by
Holm–Sidak pairwise comparisons. All statistical tests were evaluated at the
p ≤ 0.05 level. Estimation statistics were used for experiments with low
sample size (e.g., n < 5) or with data that were not normally distributed
(www.estimationstats.com) [44].
RESULTS
Striatal Zn2+ is low in human cocaine users and correlates
with cocaine intake
The highest DAT density in the brain is found in the striatum [28],
a region heavily implicated in cocaine addiction [45–48]. Human
drug users are characterized by nutritional deficiencies and
dysregulated blood and hair Zn2+ content [33–38] but whether
they show deficits in striatal Zn2+ is unknown. To assess this, we
performed elemental profiling using TXRF in postmortem striatal
tissue derived from humans whose primary cause of death was
attributed to cocaine abuse (n= 19) or matched controls (n= 20)
(Fig. 1A). Cocaine users and controls did not differ in age (Fig. 1B)
or brain pH content (Fig. 1C). We found that cocaine users had
significantly lower (unpaired t-test, t= 2.87; p= 0.006) striatal
Zn2+ levels compared to controls (Fig. 1D). This difference was
selective to Zn2+ as we did not detect significant differences in
other elements (Fig. S1). Striatal Zn2+ levels in these subjects
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significantly and negatively correlated (linear regression; F(1, 17)
= 4.5; p= 0.04) with plasma concentrations of benzoylecgonine,
(Fig. 1E) a stable cocaine metabolite indicative of recent cocaine
use [49].
Cocaine increases synaptic Zn2+ release and uptake in the
striatum
To obtain mechanistic insights in the relationship between
cocaine exposure and striatal Zn2+ levels, we examined striatal
Zn2+ content in mice exposed to cocaine. Unlike TXRF,
synchrotron X-ray fluorescence microspectroscopy (µSXRF) allows
visualization and quantification of Zn2+ in brain slices [50, 51]. We
first verified that the distribution of Zn2+, as detected by µSXRF in
the hippocampus, where synaptic Zn2+ levels are high, coincided
with distributions of ZnT3 immunolabeling and histochemically
reactive synaptic Zn2+ [52] (Fig. S2). We then performed µSXRF in
striatal sections from mice exposed to daily cocaine injections (10
mg/kg, intraperitoneal (IP), 4 days, n = 4) and euthanized 24 h
later. We found that cocaine-exposed mice had significantly
greater total Zn2+ levels in the CPu [unpaired mean difference:
Veh vs. Coc= 111; (95.0% CI 66.4, 139), p= 0.003] and in the NAc
[unpaired mean difference: Veh vs. Coc= 65.3; (95.0% CI 47.4,
98.2); p < 0.001] compared to vehicle-injected mice (n = 5) (Fig.
2A, B). There was no significant difference in Ctx [unpaired mean
difference: Veh vs. Coc = 77.8; (95.0% CI 85.1, 141); p= 0.09].
ZnT3 KO mice lack the ability to package Zn2+ into synaptic
vesicles and by extension cannot release synaptic Zn2+ [10]. We
hypothesized that the increase in cocaine-induced striatal Zn2+
we observed in mice was mediated via ZnT3. To assess this, we
first confirmed that ZnT3 KO mice lack histochemically reactive
[52] synaptic Zn2+. In agreement with prior findings [53], we found
that synaptic Zn2+ was enriched in discrete areas including medial
cortical regions, dorsomedial CPu, and medial NAc in WT mice
(Fig. 2C) and as expected, ZnT3 KO mice completely lacked
synaptic Zn2+ (Fig. 2D). We then exposed WT and ZnT3 KO mice to
daily vehicle (n= 6 WT, n= 9 KO), a single (20 mg/kg/day, IP)
cocaine injection (SC) (n= 4 WT, n= 4 KO) or repeated cocaine
(RC) (20 mg/kg/day for 8 days, IP) (n= 5 WT, n= 4 KO) injections
and euthanized them 24 h later followed by dissection of medial
frontal Ctx and striatum and assessment of Zn2+ using TXRF.
Vehicle-treated ZnT3 KO mice had significantly lower Zn2+ than
vehicle-treated WT mice in Ctx (Fig. S3), where ZnT3 expression
and synaptic Zn2+ pools are high (Fig. 2C). In contrast, vehicle-
treated WT and ZnT3 KO mice did not differ in striatal Zn2+, as
synaptic Zn2+ levels in this region are low (Fig. 2E, F) and
differences under these basal circumstances were below the
detection limit of TXRF (Fig. 2E). WT mice exposed to a SC injection
did not differ in striatal Zn2+ compared to vehicle-treated WT mice
[shared control (WT VEH) comparison; unpaired mean difference:
vehicle vs. SC = 1.52; (95.0% CI -0.31, 2.84), p = 0.07] (Fig. 2E, F). In
agreement with results from our µSXRF experiments (Fig. 2A, B),
WT mice exposed to RC injections had significantly greater striatal
Zn2+ content than vehicle-treated WT mice [unpaired mean
difference: vehicle vs. RC= 3.41; (95.0% CI 0.76, 6.87), p= 0.03]
(Fig. 2E, F). In contrast, cocaine exposure did not lead to any
differences in striatal Zn2+ in ZnT3 KO mice (Fig. 2E, F).
As a trace element, Zn2+ is challenging to study in vivo.
Consequently, in vivo brain Zn2+ kinetics have not been
previously described. However, ex vivo studies using radioactive
65ZnCl2 have shown that Zn
2+ has unique brain kinetics, uptake,
and biodistribution profiles. Specifically, systemic injection of
65ZnCl2 takes about 6 days to reach maximal brain uptake [54].
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Fig. 1 Striatal Zn2+ is low in human cocaine users and correlates with cocaine intake. A Schematic showing sampled region (caudate) from
postmortem human brain samples. B Cocaine users and control subjects did not differ in age or (C) in tissue pH. (D) Cocaine users showed
significantly lower striatal Zn2+ levels compared to control subjects. (E) Striatal Zn2+ levels in cocaine users significantly correlated with
plasma benzoylecgonine levels (ppm – parts per million). **p ≤ 0.01, *p ≤ 0.05. All data expressed as Mean ±SEM.
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Similarly, another study estimated Zn2+ turnover in the brain to be
a slow process, taking ~7 days [55]. Importantly, the ex vivo brain
distribution of systemically administered 65ZnCl2 is dependent on
neuronal activity [56] and overlaps with both distribution of ZnT3
protein and histochemically reactive Zn2+ [54], suggesting that
the majority of Zn2+ uptake to the brain is in the form of synaptic
Zn2+. In agreement with this, studies have shown that 65ZnCl2 is
transported throughout the brain in a trans-synaptic manner [57].
Finally, like synaptic Zn2+ [31], 65ZnCl2 brain uptake is dependent
on dietary Zn2+ intake [58]. Collectively, these studies indicate that
65ZnCl2 brain uptake can be used as a measure of synaptic Zn
2+
turnover/metabolism. Interestingly, 65Zn produces annihilation
photons at 511 keV at a low (~3%) abundance and has a physical
half-life of ~244 days. We reasoned that these physical
characteristics would be sufficient for noninvasive and long-
itudinal measurements of 65ZnCl2 uptake and kinetics using
positron emission tomography (PET) and thus could provide
in vivo assessments of brain Zn2+ turnover/metabolism. To
confirm, WT (n= 2) and ZnT3 KO (n= 2) mice were injected
intravenously (IV) with 2 µCi/g 65ZnCl2 and scanned using PET.
Owing to the slow kinetics and long biological and physical half-
lives of Zn2+ [54], mice were scanned longitudinally at different
days after 65ZnCl2 injection (Fig. 2G).
65Zn showed rapid brain
uptake, exhibited slow brain clearance, and was detected in the
brain up to 14 days after injection (Fig. 2G, H and Fig. S4). ZnT3 KO
mice had lower brain uptake of 65ZnCl2 at 7- and 14 days post
injection compared to WT mice (Fig. 2H). This was confirmed
ex vivo using autoradiography, which showed that 65Zn brain
distribution overlapped with distribution of synaptic Zn2+ and
ZnT3 protein in WT mice (Fig. 2I and Fig. S5). Notably, whereas
ZnT3 KO mice did show some minimal 65ZnCl2 uptake, perhaps
representing nonspecific uptake or a result of other zinc
transporters expressed in the brain [59], the distribution of
65ZnCl2 uptake in KO mice was largely absent from ZnT3-rich
regions, indicating that it did not represent the synaptic Zn2+
pool. Next, to examine effects of cocaine on 65ZnCl2 brain uptake,
we injected mice with 65ZnCl2 as above followed by daily vehicle
(n= 4) or cocaine (n= 3) injections (20 mg/kg/day, IP, 8 days) and
performed PET. Compared to vehicle, cocaine significantly (one-
way anova, treatment main effect, t contrast (1, 4)=2.13; p =
0.049) increased uptake of 65ZnCl2 in brain regions with high ZnT3
and synaptic Zn2+ levels, including the prelimbic, cingulate,
sensory cortices, NAc, hippocampus, and amygdala but decreased
it in areas of low ZnT3 and synaptic Zn2+ levels like thalamus
(Fig. 2J).
Synaptic Zn2+ release increases the in vivo potency of cocaine
on striatal DA neurotransmission
In vitro studies indicate that Zn2+ binds to the DAT and causes (i)
DA reuptake inhibition and (ii) increased cocaine-DAT binding
[18, 21, 22, 60, 61]. We reproduced these findings using mouse
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Fig. 2 Cocaine increases synaptic Zn2+ release and uptake in the striatum. A Representative synchrotron X-ray fluorescence
microspectroscopy (µSXRF) Zn2+ maps from vehicle- or cocaine-treated mice. B Cocaine-treated mice had significantly greater Zn2+ (AU-
arbitrary units) than vehicle-treated mice in caudate putamen (CPu) and nucleus accumbens (NAc). C Representative Timm- and cresyl violet-
co-stained sections from a wild-type (WT) and D a ZnT3 knockout (KO) mouse. E Zn2+ content measured using TXRF in wild-type and ZnT3
knockout mice exposed to vehicle (VEH), a single cocaine injection (SC) or repeated cocaine injections (RC) injections. F Wild-type mice
exposed to RC had significantly greater Zn2+ levels compared to VEH-treated WT mice. G PET experimental timeline and representative
horizontal 65Zn PET/CT images from wild-type and ZnT3 knockout mice scanned at 14 days after 65ZnCl2 administration. H
65ZnCl2 brain
uptake expressed as mean standard uptake value (mSUV) in wild-type and knockout mice scanned at 3, 7 and 14 days after injection.
I Representative 65ZnCl2 autoradiograms from wild-type and ZnT3 knockout mice scanned using PET at day 15 after
65ZnCl2 administration
and then euthanized for postmortem verification. J Statistical contrasts from voxel-wise statistical parametric mapping analyses from vehicle-
or cocaine-treated mice exposed to 65ZnCl2 PET imaging. ppm parts per million. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. All data expressed as Mean
± SEM.
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achievable concentration (10 µM) of Zn2+ [1] significantly
increased [unpaired mean difference: 0 vs. 10 µM=−0.627;
(95.0% CI −0.86, −0.41), p < 0.001] cocaine binding and affinity
to the DAT (Fig. 3A, B, Fig. S6). A higher, supraphysiological
concentration (1 mM), decreased [unpaired mean difference: 0 vs.
1000 µM= 2.51; (95.0% CI 0.88, 3.43), p= 0.06] cocaine affinity
(Fig. 3A, B). In agreement with the above results, 10 µM Zn2+ also
significantly increased binding of [3H]WIN-35,428 to the DAT in
tissue sections (n= 4 mice) (unpaired t-test, t= 4.03; p= 0.007)
(Fig. 3C).
To assess cocaine’s in vivo effects at the DAT as a function of
synaptic Zn2+, we performed in vivo FSCV in the striatum of WT (n
J.L. Gomez et al.
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= 4) and ZnT3 KO (n= 4) mice. Electrical stimulation of the medial
forebrain bundle was used to evoke DA release in the striatum
followed by escalating cocaine injections (5, 10, 20 mg/kg, IP) (Fig.
3D). WT and ZnT3 KO mice did not differ in baseline DA release or
clearance (Fig. S7). DA release: compared to vehicle, we found that
5, 10, and 20mg/kg cocaine significantly increased electrically-
evoked extracellular DA release in WT mice, but ZnT3 KO mice
only showed a significant increase at 20 mg/kg cocaine (Fig. S7).
ZnT3 KO mice also showed significantly lower electrically evoked
extracellular DA release compared to WT mice (two-way RM
anova; genotype × time interaction, F(19, 114)= 5.46; p < 0.001)
(Fig. 3E, G). DA clearance: compared to Vehicle, 5, 10, and 20mg/kg
cocaine significantly decreased DA clearance in WT mice as
compared to Vehicle, but ZnT3 KO mice only showed significantly
lower DA clearance at 20 mg/kg cocaine (Fig. S7). ZnT3 KO mice
showed significantly greater DA clearance in response to cocaine
compared to WT mice (two-way RM anova; genotype × time
interaction, F(19, 114)= 2.35 p= 0.0029) (Fig. 3F, H).
Synaptic Zn2+ release potentiates cocaine locomotor
sensitization, reward, seeking and is required for cocaine-
induced increases in DAT
We hypothesized that cocaine-induced synaptic Zn2+ release
would modulate cocaine-related behavior. To examine this, we
first tested ZnT3 KO mice for development and expression of
cocaine-induced locomotor sensitization. WT (n= 15) and ZnT3
KO mice (n= 16) both developed locomotor sensitization to daily
injections of cocaine (10 mg/kg/day, IP, 5 days) (two-way RM
anova with Holm–Sidak multiple comparisons, genotype × session
interaction, F(3, 59)= 7.07; p= 0.004) (Fig. 4A). However, ZnT3 KO
mice (n= 16) showed significantly lower locomotor activity
compared to cocaine-treated WT mice on Day 1 (t= 3.09; p=
0.01) and Day 5 (t= 3.22; p= 0.009) of the procedure. As
expected, WT mice injected with cocaine showed significantly
greater locomotor activity than vehicle-treated WT (n= 16) mice
on Day 1 (t= 5.54; p < 0.001) and Day 5 (t= 8.71; p < 0.001). KO
mice injected with cocaine showed significantly greater locomotor
activity than vehicle-treated KO (n= 16) mice on Day 5 (t= 5.68; p
< 0.001) but not on Day 1 (t= 2.48; p= 0.08). One week later,
vehicle-treated and cocaine-treated mice were tested for expres-
sion of cocaine locomotor sensitization via exposure to escalating
cocaine injections (5, 10, and 20mg/kg, IP). WT mice with prior
cocaine exposure (cocaine-treated) (n= 9) showed significantly
greater (2-way RM anova with Holm–Sidak multiple comparisons,
genotype × time interaction, F(79, 1343)= 1.85; p < 0.001) expres-
sion of cocaine locomotor sensitization at 5 (66 min; t= 3.65; p=
0.02, 69 min; t= 3.72; p = 0.01) and 10mg/kg cocaine (123 min; t
= 5.24; p < 0.001, 126 min; t= 6.03; p < 0.001, 129 min; t= 5.19; p
< 0.001, 132 min; t= 3.75; p= 0.01, 135min; t= 3.54; p= 0.03)
compared to vehicle-treated WT mice (n= 10) (Fig. 4B). In
contrast, cocaine-treated KO mice (n= 10) did not show a
significant increase in locomotor activity (two-way RM anova,
genotype × time interaction, F(79, 1422)= 0.9197; p= 0.67)
compared to vehicle-treated KO mice (n= 10) (Fig. 4C). Neither
WT nor ZnT3 KO cocaine-treated mice differed from the
corresponding vehicle-treated mice at a 20mg/kg dose of cocaine
(Fig. 4B, C).
Cocaine exposure increases DAT levels [47, 48, 62] which is
thought to serve as a compensatory adaptation to DAT blockade
after RC exposure. We hypothesized that ZnT3 KO mice, which
lack cocaine-induced Zn2+ release and expression of cocaine-
induced locomotor sensitization, would be insensitive to cocaine-
induced increases in striatal DAT. To test this, mice from the above
sensitization experiments were euthanized 24 h after the last
cocaine injection, the striatum was dissected, and DAT binding
assays were performed using [3H]WIN-35,428 (three repetitions
per curve, in triplicate) (one-way ANOVA: F(3, 8)= 6.23; p= 0.01).
Pairwise comparisons (Holm–Sidak) showed that vehicle-treated
WT mice (n= 6) did not differ from vehicle- or cocaine-treated
ZnT3 KO mice (n= 6) in [3H]WIN-35,428 binding (Fig. 4D).
However, cocaine-treated WT mice (n= 6) showed a trend toward
greater [3H]WIN-35,428 binding (t= 2.21; p= 0.058) compared to
vehicle-treated WT mice (n= 6) and significantly greater [3H]WIN-
35,428 binding than both vehicle-treated (n= 6) (t= 4.14; p=
0.009) and cocaine-treated KO mice (n= 6) (t= 3.12; p= 0.02).
Next, we tested whether synaptic Zn2+ release is involved in
cocaine reward by assessing the extent to which ZnT3 KO mice
develop cocaine CPP. As expected, we found that WT mice
showed significant preference for a chamber paired with cocaine
(one sample Wilcoxon (non-parametric) test with theoretical
median set to 0) at 5 (n= 8) (p= 0.007; 95% CI: 41.3–336.1), 10
(n= 9) (p= 0.003; 95% CI: 59.2–297.3), and 20 (n= 8) (p= 0.01;
95% CI: −9.8 to 258.4) mg/kg. In contrast, ZnT3 KO mice did not
show significant preference for the chamber paired with cocaine
at any dose: 5 mg/kg (n= 7) (p= 0.21; 95% CI: −118.8 to 256.2),
10 mg/kg (n= 9) (p= 0.07; 95% CI: −47.2 to 208.5) and 20mg/kg
(n= 7) (p= 0.10; 95% CI: −140.6 to 159.3) (Fig. 4E).
Finally, we examined whether synaptic Zn2+ is involved in
intravenous cocaine SA. WT mice (n= 9) showed robust
acquisition of cocaine SA (1 mg/kg/infusion for 13 days), as
evidenced by significantly greater (Mixed effects anova with
Holm–Sidak multiple comparisons); genotype × session interac-
tion, F(12, 190)= 6.12; p < 0.001) and sustained responding on
the cocaine-reinforced active lever over the non-reinforced
inactive lever on days 11 and 12 (session 11: t= 6.48; p <
0.001, session 12: t= 4.25; p= 0.009) (Fig. 4F). In contrast, ZnT3
KO mice (n= 9) failed to acquire cocaine SA at the 1 mg/kg/
infusion dose (Fig. 4H) as they did not show any significant
differences (two-way RM anova with Holm–Sidak multiple
comparisons, genotype × session interaction, F(12, 192)= 1.27;
p= 0.23) in cocaine-reinforced vs. inactive lever pressing. All
mice were then switched to a lower cocaine dose (0.5 mg/kg/
infusion for 7 days). WT mice (n= 7) immediately reached the
maximum allowed number (50) of infusions (Fig. 4G) and showed
significantly greater cocaine-reinforced presses (two-way RM
anova with Holm–Sidak multiple comparisons, lever main effect,
F(1, 12)= 116.7; p < 0.001) compared to inactive lever presses
(session 1: t= 12.54; p < 0.001, session 2: t= 5.03; p= 0.004,
session 3: t= 7.91; p < 0.001, session 4: t= 9.39; p < 0.001, session
5: t= 15.45; p < 0.001, session 6: t= 23.33; p < 0.001, session 7: t
= 10.42; p < 0.001). At the 0.5 mg/kg/infusion dose, ZnT3 KO
Fig. 3 Synaptic Zn2+ release increases the in vivo potency of cocaine on striatal DA neurotransmission. A Competition binding curves of
cocaine and ZnCl2 against [
3H]WIN-35,428 in mouse striatal tissue. B 10 µM ZnCl2 significantly increased and 1 mM ZnCl2 decreased affinity of
cocaine in mouse striatum (Ki (±SD)) values in nM; Cocaine: 0 µM Zn, 63 ± 39; 0.1 µM Zn, 77 ± 57; 10 µM Zn, 43 ± 31; 1000 µM Zn, 611 ± 843 and
WIN-35,428: 0 µM Zn, 9 ± 1.2; 0.1 µM Zn, 9.2 ± 0.8; 10 µM Zn, 5.1 ± 1.1; 1000 µM Zn, 13.4 ± 1.8). C Autoradiograms at the level of mouse striatum
showing that 10 µM ZnCl2 significantly increased [
3H]WIN-35,428 binding. D Experimental design of fast scan cyclic voltammetry (FSCV)
experiment. E Representative FSCV color plots from wild-type and F ZnT3 knockout mice showing changes in electrically-evoked dopamine
(DA) after a 10mg/kg IP cocaine injection. G FSCV time-course plots showing significantly lower percent change in electrically-evoked DAMax
and H faster DA Clearance rate in ZnT3 knockout compared to wild-type mice as a function of vehicle or escalating IP cocaine injections. *p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001. All data expressed as Mean ± SEM.
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mice took longer (3 sessions) to learn to discriminate the
cocaine-reinforced active lever over the inactive lever and also
took longer (five sessions) to reach 50 infusions (Fig. 4I).
Eventually, ZnT3 KO mice (n = 7) showed significantly greater
cocaine-reinforced presses (two-way RM anova with Holm–Sidak
multiple comparisons, lever × time interaction, F(6, 71) = 3.9; p =
0.002) compared to inactive lever presses (session 3: t = 4.74; p =
0.007, session 4: t = 7.03; p = 0.002, session 5: t = 8.86; p < 0.001,
session 6: t = 9.82; p < 0.001, session 7: t = 4.01; p = 0.04). After
acquisition of cocaine SA, mice were tested at lower doses of
cocaine. WT and KO mice did not differ in the number of cocaine
infusions at these lower doses (Fig. S8). However, compared to
WT mice (n = 6), KO mice (n = 5) showed significantly lower
cocaine intake (mixed effects RM analysis with Holm–Sidak
multiple comparisons, genotype × dose interaction, F(4, 44) =
2.92) at 1 mg/kg/inf. (t = 3.26; p = 0.001) and at 0.125 mg/kg/inf.
(t = 2.03; p = 0.04) doses (Fig. 4J). Mice were then assessed for
extinction of cocaine SA, but no genotype differences were
observed (Fig. 4K). After mice had extinguished their lever
responding for cocaine, they were tested for reinstatement
(relapse) responding to a cocaine priming injection (10 mg/kg,
IP). WT mice (n = 5) showed reinstatement of cocaine SA and
significantly greater active lever presses (two-way RM anova with
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F(1, 10) = 5.09; p= 0.04) after cocaine priming (t = 3.17; p =
0.005) compared to ZnT3 KO mice (n = 5), which did not
reinstate (Fig. 4L, M). WT mice (n = 5) and ZnT3 KO mice (n = 5)
did not differ in inactive lever responding (two-way RM anova
with Holm-Sidak multiple comparisons, genotype × dose
interaction, F(1, 10) = 0.17; p = 0.68) during cocaine-primed
reinstatement.
Dietary Zn2+ deficiency decreases brain Zn2+ and attenuates
cocaine locomotor sensitization, reward, and striatal DAT
binding
Synaptic Zn2+ levels and ZnT3 expression are modulated by
dietary Zn2+ intake [30, 31]. Chronic drug abuse (including
cocaine) in humans is associated with malnutrition and dysregu-
lated peripheral Zn2+ levels [33–38]. However, whether dietary
Zn2+ availability can modulate the behavioral effects of cocaine
has not been previously reported.
To examine this, we fed mice, for approximately one month,
diets that were custom-formulated by a commercial vendor to
contain either 30 (considered an adequate level of Zn2+ intake) or
5 (a low amount of Zn2+ intake) ppm Zn2+. We first verified the
Zn2+ content of each diet using TXRF. According to our
measurements, the 30 ppm diet contained ~28 ppm Zn2+ and
the 5 ppm diet contained ~8 ppm Zn2+ (Fig. 5A) (we will however
refer to them here as 30 and 5 ppm Zn2+ diets to remain
consistent with prior studies that have used similar formulations).
Mice fed a 5 ppm Zn2+ diet (n = 32) did not differ in body weight
from mice fed a 30 ppm Zn2+ diet (n = 32) (Fig. 5B). Mice fed a 5
ppm Zn2+ diet (n = 32) showed a significant decrease (two-way
RM anova with Holm-Sidak multiple comparisons; genotype ×
time interaction, F(15, 930) = 10.07; p < 0.001) in food intake
3 days (t = 11.37; p < 0.001) after diet initiation compared to mice
fed a 30 ppm diet (n = 32) though soon afterward normalized to
the same levels of intake (Fig. 5C). The low Zn2+ diet was effective
in decreasing brain Zn2+ content as mice fed a 5 ppm Zn2+ diet (n
= 7) showed significantly lower Zn2+ levels in frontal Ctx
(unpaired t-test; t = 3.15; p = 0.01) compared to mice fed a 30
pm Zn2+ diet (n = 5) as assessed via TXRF (Fig. 5D).
Next, we performed cocaine locomotor sensitization in 30 ppm
and 5 ppm mice using the same procedures as in the above ZnT3
KO experiments. Mice fed 5 ppm or 30 ppm Zn2+ diets did not
differ in the development of cocaine locomotor sensitization (Fig.
5E). 30 ppm diet-fed mice injected with cocaine (n = 14) showed
significantly greater locomotor activity (two-way RM anova with
Holm-Sidak multiple comparisons; genotype × session interaction,
F(3, 52) = 23.57; p < 0.001) than 30 ppm diet-fed mice injected
with vehicle (n = 14) at Day 1 (t = 8.29; p < 0.001) and Day 5 (t =
14.27; p < 0.001). Similarly, 5 ppm mice injected with cocaine (n =
14) showed significantly greater locomotor activity compared to 5
ppm mice injected with vehicle (n = 14) at Day 1 (t = 6.95; p <
0.001) and Day 5 (t = 13.95; p < 0.001). 30 ppm mice injected with
cocaine also showed significantly greater locomotor activity at
Day 5 than at Day 1 (t = 9.98; p < 0.001) and 5 ppm mice injected
with cocaine also showed significantly greater locomotor activity
at Day 5 than at Day 1 (t = 10.06; p < 0.001) (Fig. 5E). Seven days
later, mice were examined for expression of cocaine locomotor
sensitization. We found that cocaine-treated mice fed the 30 ppm
diet (n = 6) showed significantly greater expression of cocaine
locomotor sensitization (two-way RM anova with Holm–Sidak
multiple comparisons; genotype × time interaction, F(79, 790) =
3.98; p < 0.001) at 5 (66 min; t = 5.69; p < 0.001, 69 min; t = 4.68; p
< 0.001, 72 min; t = 3.76; p = 0.01, 75 min; t = 3.78; p = 0.01,
78 min; t = 4.29; p = 0.001, 81 min; t = 3.79; p = 0.01, 84 min; t =
4.23; p = 0.002), 10 mg/kg (123 min; t = 5.37; p < 0.001, 126 min; t
= 7.42; p < 0.001, 129 min; t = 6.99; p < 0.001, 132 min; t = 6.58; p
= 0.01, 135 min; t = 5.08; p = 0.03, 138 min; t = 5.36; p = 0.03,
141 min; t = 4.39; p = 0.03, 144 min; t = 4.14; p = 0.03, 147 min; t
= 3.78; p = 0.03) and 20mg/kg cocaine (183 min; t = 3.43; p =
0.04) compared to vehicle-treated mice fed the same 30 ppm diet
(n = 13) (Fig. 5F). In contrast, cocaine-treated mice fed the 5 ppm
diet (n = 6) did not show a significant difference in expression of
locomotor sensitization compared to vehicle-treated mice fed the
5 ppm diet (n = 6) (two-way RM anova with Holm-Sidak multiple
comparisons; genotype × time interaction, F(79, 790) = 0.9342; p
= 0.64) (Fig. 5G).
Next, we tested whether mice fed 30 ppm and 5 ppm Zn2+ diets
differed in cocaine preference using the same CPP procedure as in
ZnT3 KO mice. Mice fed the 30 ppm Zn2+ diet showed significant
preference (one sample Wilcoxon test with theoretical median set
to 0) for the chamber paired with cocaine at 5 mg/kg (n = 8) (p =
0.007; 95% CI: 45.8–205.5), 10 mg/kg (n = 8) (p = 0.007; 95% CI:
42.6–245.4), and 20 mg/kg (n = 7) (p = 0.003; 95% CI: −6.0 to
149.6). Mice fed a 5 ppm Zn2+ diet showed significant preference
(one sample Wilcoxon test with theoretical median set to 0) for the
chamber paired with cocaine at 10 mg/kg (n = 8) (p = 0.039; 95%
CI: −79.8 to 298.0), and 20 mg/kg (n = 8) (p = 0.007; 95% CI:
26.2–185.9) but not at 5 mg/kg (n = 8) (p = 0.10; 95% CI: −30.1 to
125.7) (Fig. 5H).
Finally, we examined whether dietary Zn2+ availability had any
effects on DAT binding in the striatum. Mice fed 30 ppm and 5
ppm Zn2+ diets and exposed to escalating cocaine injections (5,
10, and 20mg/kg, IP, one injection/h) were euthanized 24 h after
the last injection and their brains were assessed for striatal [3H]
WIN-35,428 binding. We found that mice exposed to cocaine and
a 5 ppm Zn2+ diet (n = 6) showed significantly lower striatal DAT
binding (Fig. 5I) (unpaired t-test; t= 9.63; p < 0.001) (3 repetitions
Fig. 4 Synaptic Zn2+ release potentiates cocaine locomotor sensitization, reward, seeking and is required for cocaine-induced increases
in DAT. A ZnT3 knockout (KO) mice injected with 10 mg/kg cocaine (COC) showed significantly lower locomotor activity compared to
cocaine-injected wild-type (WT) mice. Compared to vehicle, cocaine significantly increased locomotor activity in both WT and KO mice on Day
5 but only in WT mice on Day 1. B Cocaine-treated WT mice showed significantly greater expression of cocaine locomotor sensitization at 5
and 10 mg/kg cocaine compared to vehicle-treated WT mice. C Cocaine-treated ZnT3 KO mice do not differ in expression of cocaine
locomotor sensitization compared to vehicle-treated KO mice. D Cocaine-treated WTmice had significantly greater DAT binding than cocaine-
treated ZnT3 KO mice and vehicle-treated KO mice and showed a trend toward significantly greater DAT binding than vehicle-treated WT
mice. E WT mice showed significant preference for a chamber paired with cocaine at 5, 10, and 20 mg/kg. ZnT3 KO mice did now show
preference for a chamber paired with cocaine at any dose. F Wild-type mice exposed to a training dose of cocaine (1 mg/kg/inf.) showed
significantly greater cocaine-reinforced presses compared to inactive lever presses. G Once trained, WT mice were exposed to a lower cocaine
dose (0.5 mg/kg/inf.), immediately reached the maximum number of presses allowed per session, and showed significantly greater cocaine-
reinforced presses compared to inactive lever presses on all sessions. H ZnT3 knockout mice exposed to a training dose of cocaine (1 mg/kg/
inf.) did not show any significant differences between cocaine-reinforced and inactive lever pressing. I ZnT3 knockout mice exposed to a lower
cocaine dose (0.5 mg/kg/inf.) showed significantly greater cocaine-reinforced presses compared to inactive lever presses during the last five
sessions. J ZnT3 KO mice showed significantly lower cocaine intake at 1 mg/kg/inf. and at 0.125mg/kg/inf. compared to WT mice. K WT and
ZnT3 KO mice did not differ in extinction of cocaine self-administration. L After extinction of cocaine self-administration behavior, WT mice
showed reinstatement of cocaine self-administration and significantly greater active lever presses after cocaine priming compared to ZnT3 KO
mice. M WT and ZnT3 KO mice did not differ in inactive lever responding during cocaine-primed reinstatement. *p ≤ 0.05. All data except
E expressed as Mean ± SEM. Panel E is expressed as Median ± 95% CI.
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per group, in triplicate) and a decrease in cocaine affinity
compared to mice exposed to cocaine and a 30 ppm Zn2+ diet
(n = 6) (5 ppm Ki = 61 ± 26 nM; 30 ppm Ki = 46 ± 17 nM) (3
repetitions per curve, in triplicate) (Fig. 5J).
DISCUSSION
Here we show that human subjects who died of cocaine overdose
had significantly lower Zn2+ content in the striatum (caudate)
compared to matched controls. We also show that striatal Zn2+
levels in these subjects negatively correlated with plasma levels of
benzoylecgonine, indicating that low striatal Zn2+ levels were
associated with greater cocaine intake.
To further explore the relationship between cocaine exposure
and striatal Zn2+, we performed studies using mice lacking ZnT3, a
neuronal Zn2+ transporter necessary for synaptic Zn2+ release. We
found that RC injections increased striatal Zn2+ content (in CPu
and NAc) in normal mice but not in mice lacking ZnT3, indicating
that cocaine exposure increases synaptic Zn2+ levels in the
striatum via the actions of ZnT3. We also found that RC injections
increased Zn2+ uptake in regions with high synaptic Zn2+ and
ZnT3 content, including the NAc indicating that cocaine exposure
increases synaptic Zn2+ turnover/metabolism in these regions.
We hypothesized that cocaine-induced increases in synaptic
Zn2+ release would be relevant to cocaine’s in vivo actions at the
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Fig. 5 Dietary Zn2+ deficiency decreases brain Zn2+ and attenuates cocaine locomotor sensitization, reward, and striatal DAT binding.
A Total reflection X-ray spectroscopy (TXRF)-based verification of Zn2+ content in custom-made diets. B Mice fed a 5 ppm Zn2+ diet did not
differ in body weight from mice fed a 30 ppm Zn2+ diet. C Mice fed a 5 ppm Zn2+ diet showed a significant decrease in food intake 3 days
after diet initiation compared to mice fed a 30 ppm diet but did not differ at other times. D Mice fed a 5 ppm Zn2+ diet showed significantly
lower total Zn2+ in frontal/cingulate cortex compared to mice fed a 30 pm Zn2+ diet. E Mice fed 5 ppm or 30 ppm Zn2+ diets did not differ in
development of cocaine (COC) locomotor sensitization (VEH- vehicle). F Cocaine-treated 30 ppm diet mice (n = 6) showed significantly greater
expression of cocaine locomotor sensitization at 5, 10 mg/kg and 20 mg/kg cocaine compared to vehicle-treated 30 ppm mice (n = 13).
G Cocaine-treated 5 ppm mice did not show any significant difference in expression of locomotor sensitization compared to vehicle-treated 5
ppm mice. H Mice fed a 30 ppm Zn2+ diet showed significant preference for a chamber paired with cocaine at 5, 10, and 20 mg/kg. Mice fed a
5 ppm Zn2+ diet showed significant preference for a chamber paired with cocaine at 10, and 20 mg/kg but not at 5 mg/kg. I Mice exposed to
cocaine and a 5 ppm Zn2+ diet showed significantly lower DAT binding in striatum and J a mild decrease in cocaine affinity compared to mice
exposed to cocaine and a 30 ppm diet. dpm - disintegrations per minute. *p ≤ 0.05. All data except panel H expressed as Mean ± SEM. Panel H
is expressed as Median ± 95% CI.
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and cocaine. Using in vitro assays, we first confirmed that a
physiologically-relevant concentration of Zn2+ increased the
ability of cocaine to bind to DAT. Then, to extend the relevance
of this finding to an in vivo context, we used in vivo FSCV and
found that deletion of ZnT3, and hence, loss of synaptic Zn2+
release, attenuated cocaine’s effects on striatal DA neurotransmis-
sion. Consistent with this observation, mice lacking ZnT3 were
insensitive to cocaine-induced increases in striatal DAT binding
and showed attenuated behavioral responses to cocaine in several
procedures such as locomotor sensitization, CPP, and IV SA,
indicating that synaptic Zn2+ promotes cocaine sensitization,
reward, and cocaine-seeking behavior.
Zn2+ is obtained almost exclusively from the diet. Taking our
above findings into account, we reasoned that low environmental
availability of Zn2+ and specifically, reduced dietary Zn2+ intake,
would attenuate behavioral responses to cocaine. As predicted,
we found that mice exposed to a diet with low Zn2+ content
showed lower brain Zn2+ levels, decreased cocaine-induced
increases in striatal DAT binding, and attenuated behavioral
responses to cocaine compared to mice fed a diet with adequate
Zn2+ content. This indicates that low dietary Zn2+ intake
decreases brain Zn2+ levels, and attenuates cocaine locomotor
sensitization, cocaine preference, and cocaine-induced increases
in striatal DAT.
Taken together, our above findings suggest that synaptic Zn2+
release in the striatum plays a critical role in cocaine’s effects on
striatal DA neurotransmission and consequently in the neurobio-
logical and behavioral adaptations associated with cocaine
exposure. A summary depicting this proposed mechanism is
shown in Fig. 6.
The results from our experiments in mice suggest that the Zn2+
deficits we identified in humans who died from cocaine overdose
may arise from a combination of inadequate nutrition (i.e. low
dietary Zn2+ intake) and increased Zn2+ turnover/metabolism
brought upon by chronic cocaine use, although we cannot rule out
individual or combined contributions of diet, cocaine use, or use of
other drugs/substances in these effects. The negative correlation
between striatal Zn2+ content and plasma benzoylecgonine levels
in postmortem human samples, taken together with the rest of our
data, may reflect the notion that individuals with inherently low
striatal Zn2+ levels would be less sensitive to the effects of cocaine
and therefore would need to compensate by consuming more of
the drug. This would implicate Zn2+ as an environmental factor that
could influence vulnerability to the effects of cocaine and
potentially to the development of cocaine use disorders or
addiction.
Our results have important implications for both general DA-
dependent behaviors and especially for the prevention and
treatment of cocaine addiction. Specifically, our findings suggest
that dietary Zn2+ intake, and potentially, impaired Zn2+ absorp-
tion or excretion mechanisms, are implicated in cocaine reward,
seeking, and relapse. Consequently, we suggest that the Zn2+
status of patients with cocaine addiction should be taken into
consideration, especially since Zn2+ deficiency varies in preva-
lence across social demographics and is found in higher
proportion in developing countries [32].
Our findings also expand the current understanding of cocaine’s
neurobiological effects. DA and glutamate systems converge at the
level of the striatum to modulate behaviors that influence cocaine
seeking and abuse [46, 63]. Synaptic Zn2+, mediated by ZnT3, is
packaged along with glutamate in the same synaptic vesicles and is
released by glutamatergic terminals in the striatum upon neuronal
activation. As such, the cocaine-induced synaptic Zn2+ increases we
report here would be expected to accompany the well-described
increase in synaptic glutamate neurotransmission in the striatum
following RC exposure [45, 46, 64, 65]. Indeed, cocaine-induced
increases in synaptic glutamate are thought to result, in part, from
reductions in extrasynaptic glutamate arising from decreased
cystine-glutamate exchange in response to RC use [63, 66].
Specifically, cocaine-induced reductions in extrasynaptic glutamate
weaken signaling at presynaptic metabotropic glutamate receptors,
thereby increasing synaptic glutamate levels [64] and resulting in
Fig. 6 Schematic representation of the putative mechanism by which presynaptic Zn2+ modulates the effects of cocaine on dopamine
and glutamate neurotransmission in the striatum in wild-type (WT) and ZnT3 knockout mice. The image on the left shows the effect of
synaptic Zn2+ on increasing cocaine’s efficacy by binding to the DAT on dopaminergic neurons. It also acknowledges the putative effects of
Zn2+ on glutamate neurotransmission in the context of cocaine via its interaction with AMPA and NMDA receptors. The image on the right
illustrates the effect of ZnT3 deletion, and consequently the loss of presynaptic Zn2+ release, in attenuating the effects of cocaine on striatal
dopamine and glutamate neurotransmission.
J.L. Gomez et al.
12
Translational Psychiatry          (2021) 11:570 
excitatory synaptic strengthening. This mechanism may underlie
the increases in cocaine-induced synaptic Zn2+ that we observe.
Zn2+ binds to NMDA and AMPA receptors [67, 68] and it is likely
that, in addition to affecting DA neurotransmission via binding to
DAT, cocaine-induced increases in synaptic Zn2+ release may also
exert direct allosteric interactions at ionotropic glutamate
receptors to influence cocaine-dependent glutamate neurotrans-
mission, synaptic plasticity, and behaviors such as cocaine
locomotor sensitization and cocaine priming-induced reinstate-
ment of cocaine seeking [45, 46, 65, 69]. However, the precise
mechanism for how cocaine-induced Zn2+ release would lead to
such effects is complicated by the fact that Zn2+ can exert
bidirectional effects at AMPA receptors [70], it can inhibit both
synaptic and extrasynaptic NMDA receptors [68], and finally, that
cocaine induces projection- and cell type-specific adaptations in
the NAc [71], that not all NAc glutamatergic synapses release Zn2+,
and that the specific zincergic synapses, and the postsynaptic cells
they target in regions such as the NAc have not yet been defined.
For all these reasons, the specific effects of cocaine-induced Zn2+
release on glutamatergic signaling are unclear and require further
investigation.
Another possibility may be that Zn2+ interacts with cystine-
glutamate exchange mechanisms directly to produce changes in
cocaine behaviors. Indeed, we found here that ZnT3 KO mice
failed to reinstate cocaine-primed SA of cocaine, suggesting that
synaptic Zn2+ release is necessary for cocaine-primed seeking.
N-acetylcysteine (NAC) is a derivative of the amino acid cysteine
and has been proposed as a treatment for substance use disorders
[72]. NAC prevents cocaine-primed reinstatement of drug seeking
after cocaine SA by stimulating cystine-glutamate exchange [63].
Importantly, NAC also has metal-chelating capabilities (Zn2+ binds
with high affinity to cysteines [73]) and systemic administration of
NAC in mice has been shown to decrease peripheral Zn2+ levels
[74]. Accordingly, it may be possible that in addition to the effects
of NAC in decreasing cocaine-primed seeking via activation of
cystine-glutamate exchange, its effects may also be driven, in part,
via direct interaction with synaptic Zn2+. In this case, NAC would
effectively act as a Zn2+ chelating agent, decreasing synaptic Zn2+
levels, which would attenuate cocaine’s effects at the DAT and
decrease cocaine-seeking. However, this could also occur con-
comitantly to NAC’s activation of cystine-glutamate exchange,
which would increase extrasynaptic glutamate to restore pre-
synaptic metabotropic glutamate receptor tone and thereby
reduce synaptic glutamate and potentially, co-released Zn2+.
In addition to cocaine, other psychostimulants interact with the
DAT to produce their effects of behavior. We propose that the
cocaine-dependent changes in Zn2+ that we describe here are not
specific to cocaine but may also be elicited by other psychosti-
mulants that modulate DAT function and increase corticostriatal
glutamate neurotransmission [45, 46, 75], and potentially other
drugs of abuse, including alcohol [76] which is strongly associated
with Zn2+ deficiency [76].
Finally, in addition to its critical role in addiction, the DAT is the
primary molecular target for stimulant medications used in the
treatment of attention-deficit hyperactivity disorder (ADHD).
Studies indicate that medication response is reduced in Zn2+-
deficient ADHD patients [77]. Our findings here offer a mechanistic
explanation for these clinical observations and suggest that Zn2+
supplementation may improve the efficacy of stimulant-based
ADHD medications.
In conclusion, our findings expand current knowledge regard-
ing the direct pharmacological mechanism of action of cocaine
and the neurobiological mechanisms involved in cocaine’s
behavioral effects by identifying a critical role for the trace
element Zn2+ as an environmentally derived modulator of cocaine
affinity, potency, plasticity, reward, and seeking.
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